STEM

[Ramsburg]

Profile: StemCells, Inc., a biopharmaceutical company, engages in the discovery and development of adult stem cell therapeutics to treat damage to; or degeneration of major organ systems, such as the central nervous system, liver, and pancreas. The company is developing investigational new drug application, which received FDA approval to use its proprietary human neural stem cells for the treatment of neuronal ceroid lipofuscinosis, a lysosomal storage disorder; and received approval from the Institutional Review Board of the Oregon Health & Science University (OHSU) to begin the Phase I trial at OHSU Doernbecher Children's Hospital. It has a contract research and license agreement with NeuroSpheres, Ltd. StemCells was co-founded by David J. Anderson and Fred H. Gage in 1988. The company was formerly known as Cellular Transplants, Inc. It changed its name to CytoTherapeutics in 1992 and to StemCells, Inc. in 2000. StemCells is headquartered in Palo Alto, California.
Website: http://www.stemcellsinc.com
Market Cap: 193M

Trading Idea:
STEM has been trading inside a large reversal pattern for the last few months, during the recent sessions STEM started to climb with increasing volume, and momentum seems to be set for a bigger move.

This pattern can be seen as an Ascending Triangle, with top at @ $2.47 and bottom on the ascending support line @ 2.10, two weeks ago STEM had a breakout of its mid-term descending resistance line, and yesterday it had the highest close since May, making an attempt to breakout the triangle with interesting volume.

Once again, this is a technical play, where we expect short term continuation to the upside.

Trading Plan:
Buy STEM today and set a stop @ $2.25 for this position

Regards,

[422fwhp]

Nice pick.

On a side note, what charting system do you use? 

TIA...Jody

[Ramsburg]

Nice pick.

On a side note, what charting system do you use? 

TIA...Jody

Hello Jody,

I'm using Metastock Professional 8.0 (www.equis.com)

regards,

[Ramsburg]

Update:
Really nice start for this position, we’re right about the breakout expectations, and now we have a triangle projection In Play, that would be the $3.20 level (a possible short term target).
The $2.45/$2.50 zone should work as a support in case of a consolidation pullback, we’re holding this position and waiting for some upside developments…

Trading Plan:
Hold STEM with a stop @ $2.25

Regards,

[Ramsburg]

Intraday Update:
I was starting to be concerned about this position and ASTM... but today’s session is proving this is really a rebound play

A proper update will be posted during the weekend.

Regards,

[Ramsburg]

Update:
Friday was a nice day for STEM, even if the stock didn’t hold the highs of the day, the candle is still bullish and shows a lot of power on this rebound play, volume was up again
This sector is getting hot, with a lot of price action, and I believe STEM has a lot of short term potential, the target of the recent breakout is $3.20, we’ll be waiting with the same plan:

Trading Plan:
Hold STEM with a stop @ $2.25

Regards,

[Ramsburg]

Update:
STEM is showing some volatility at these levels, although we have no reasons yet to discard this upside swing. We are just moving our stop a little higher and wait some price developments here.

Trading Plan:
Hold STEM with a stop @ $2.40

Regards,

[Ramsburg]

Update:
No special developments here, STEM is still consolidating the recent gains, trading nicely above the breakout level.

Trading Plan:
Hold STEM with a stop @ $2.40

Regards,

[danman3459]

StemCells, Inc. to Present at The Rodman & Renshaw 8th Annual Healthcare Conference
Oct 27 2006, 7:30 AM EST

BIOWIRE

StemCells, Inc. (NASDAQ: STEM) today announced that Rodney Young, Chief Financial Officer, will present a corporate update at the Rodman & Renshaw 8th Annual Healthcare Conference scheduled for November 6-8, 2006 at the New York Palace Hotel in New York City. Mr. Young is scheduled to speak at 11:40 a.m. EST on Tuesday, November 7, 2006. There will be a breakout session following the presentation at which Mr. Young will be available to answer questions about the Company.

A webcast of the presentation can be accessed via the following link: http://www.wsw.com/webcast/rrshq10/stem/. The replay of the webcast will be available for 90 days following the presentation.

About StemCells, Inc.

StemCells, Inc. is a clinical-stage biotechnology company leading the discovery, development and commercialization of cell-based therapeutics to treat diseases of the nervous system, liver and pancreas. The Company's programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to identify, isolate and purify human neural stem cells from brain tissue. The Company is currently conducting a Phase I clinical trial of its proprietary human neural stem cells (HuCNS-SC(TM)) for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative condition affecting infants and young children. StemCells has approximately 40 U.S. and 100 non-U.S. patents. Further information about the Company is available on its web site at: www.stemcellsinc.com.

Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (the "Company") and its ability to conduct clinical trials as well as its research and product development efforts. The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainty whether results obtained in the animal models of infantile NCL will be able to be translated into treatment for humans; uncertainty as to whether the FDA or other applicable regulators or review boards will permit the Company to continue clinical testing in NCL despite the novel and unproven nature of the Company's technology; uncertainties regarding the timing and duration of any clinical trials; uncertainties regarding the Company's ability to obtain the increased capital resources needed to conduct the later-phase clinical trials necessary for regulatory approvals of HuCNS-SC; uncertainty regarding the validity and enforceability of the Company's patents; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company's stem cell programs will prove safe and clinically effective and not cause tumors or other side effects; uncertainty as to whether the Company will achieve revenues from product sales or become profitable; and other factors that are described under the heading "Risk Factors" in Item 1A of the Company's Annual Report on Form 10-K.

[Ramsburg]

Update:
STEM had a fantastic session, with a nice price advance into new highs for this rebound, with explosive volume, and touching the $3.20 level, which is the technical target for this swing:

This sector is getting hot, with a lot of price action, and I believe STEM has a lot of short term potential, the target of the recent breakout is $3.20, we’ll be waiting (...)

Something is definitively going on with this sector… But in this case, we’ll be taking a profit out of the table, so we’ll sell strength, and probably we’ll be back later after further consolidation.
After a candlestick like this one, and especially with this volume, STEM has the potential to reach something like $3.50 short term which is the first resistance nearby.

Trading Plan:
SELL STEM today during the session (suggested exit is above $3.20, but we’ll not be setting a specific plan here).

Regards,

[Ramsburg]

Sold this position @ $3.21 for the 3SOF Portfolio

regards,

[Ramsburg]

Trading Idea:
Looks like we made a good decision, exiting STEM @ $3.21

Earnings were out, and the market reaction was negative, bringing STEM below $3.00 again and setting some short term corrective mood for this stock… Although, we expect this to be a temporary step back on a mid term up swing that will probably take STEM above $3.50, so we’re willing to take another shot into this stock.

Standby Trading Plan:
Buy STEM again between $2.70 and $2.80

[Melf Elf]

Trading Idea:
Looks like we made a good decision, exiting STEM @ $3.21

VERY good decision, Frederick!    Nice trade.  Applause.

[nofear]

I bought at 2.80, the low of the day applaud !

[masternic35]

Hi Nofear,

nice trade

I'm still waiting on the sidelines. Technically, I fear there is a 70% chance to see the stock going to 2.6$ where there is a support before jumping to higher skies.

but that's JMHO